Cases

A producer of a high-margin specialty ingredient faced patent expiry and the prospect of generic competition from producers in Mexico and India. The strategic question carried three live alternatives: defend through patent litigation, accept generic competition and compete on cost and service, or forward-integrate into the downstream end-use category — placing the company in direct competition with one of its largest customers. Each path carried different probability-weighted outcomes and different irreversibility profiles.

Decision-tree analysis was used to map the choice across competitive responses, regulatory contingencies, and customer reactions, with risk profiles developed for the leadership team and contingency plans built behind each major branch. The work surfaced a path that was not the highest expected-value option in isolation but produced the most defensible outcome under adverse competitor moves — and identified the conditions under which a different branch should be activated.

Documented eight-figure value creation.

An industrial services group submitted a multi-year energy performance bid to a major North American big-box retailer covering several thousand stores. The economics were structured at the per-store unit level — a base service fee plus performance pricing tied to delivered energy savings — with approximately $4.5 million in customer savings per store from each percentage point of efficiency improvement, and a deal scale that rolled up to several billion across the store base.

Twelve scenarios were developed across three structural dimensions: the shape of the share-of-savings curve (decreasing, constant, or increasing seller share as savings grow), the level of discount applied to the base fee (30% or 45%), and the energy-savings range over which the discount was recovered (5–6% or 5–7%). Each scenario was evaluated as a probability-weighted bilateral value calculation, expressing the customer's expected ROI and the seller's expected incremental revenue across the realistic savings distribution.

The recommendation followed from the math rather than the rhetoric: a structure offering a substantial discount on the base fee in exchange for a defined share of incremental savings, producing customer ROI of forty-seven percent in the most likely savings band and an attractive risk-adjusted revenue position for the seller. Twelve scenarios mapped a trade-off space between roughly twenty-seven and forty-seven percent customer ROI; the recommendation was the point on that surface where both parties were materially better off than under the original proposal.

Customer ROI 27–47% across modeled scenarios on a multi-thousand-store, multi-billion-dollar deal; recommended structure produced 47% customer ROI in the most likely savings band with corresponding seller upside under achievement.

A $2.3 billion global healthcare company responded to government and institutional tenders across 98 countries with no consistent bid framework. Response times were long, win rates were uneven, and pricing decisions reflected local urgency more than coordinated strategy. Country managers had wide latitude and limited tools.

A structured bid system was developed combining country-level competitive calibration, value-based price anchoring, and a discount authority matrix that surfaced the trade-off between win probability and realized margin on every deal. The system was designed for country-manager use rather than central command, on the principle that local judgment is the binding constraint on tender quality and the methodology's job is to organize that judgment, not replace it.

Bid response time 19→9 days; win rate 52%→64% with a 3.4% price lift; projected 4× ROI on the twelve-month beta and 15× ROI on the twenty-four-month global rollout.

The acute-care division of a Fortune 50 healthcare distributor was the third-ranked player in a market dominated by two competitors each holding roughly forty percent share, against the company's twenty percent. A head-on volume contest against the two scale incumbents was structurally unwinnable. The strategic question was where to compete — which segment of the buyer base could be approached on differentiated value rather than on scale.

The segmentation thesis was sharp: mid-sized hospitals were the sweet spot. Large enough to gain meaningful operational and economic benefit from acquiring the supplies-management software the company had recently brought in through acquisition; small enough that they had not already deployed an equivalent system. The pricing structure bundled the physical supplies and the management software with a gain-sharing layer tying customer fees to documented supply-chain savings — making the value of the technology economically legible to procurement teams that could not easily justify capital purchases of comparable systems on their own.

The same bilateral value methodology used in the energy services bid above was applied here to a product-plus-software bundle in a regulated buyer environment, with the gain-sharing structure functioning as the mechanism that aligned the seller's incentive with the customer's realized outcome.

Bundled-pricing strategy and gain-sharing structure adopted across the acute-care division, targeted at the mid-size hospital segment as the differentiated growth lane.

A leading global producer of corn and soybean seed faced sustained market-share losses to a competitor with a stronger trait portfolio, alongside aggressive price competition from a third major and a long tail of regional suppliers. Internal opinion was divided on the diagnosis: was the business losing share because price was too high, because the trait portfolio was behind, or because the sales organization had lost discipline on discount and exception pricing. The pricing process itself had become an exception-management exercise rather than a strategy.

The engagement opened with structured internal-hypothesis formation across senior management, marketing, R&D, and sales, followed by a blind external interview program with twenty growers across five states stratified by farm size and land quality. The internal-versus-external gap analysis was decisive: corporate believed it was offering better value than competitors at a higher price; growers ranked the company below the price/value equilibrium while ranking competitors at or above it. Yield was the dominant decision criterion, followed by input traits — both areas where the competitor had moved ahead — with invoiced price and discounts following. Switching costs were negligible.

The strategic finding was that the business was product-driven, not price-driven. Cutting prices to defend share would not produce switchback once a customer had moved to a competitor (the competitor would then become the incumbent), and would constrain value capture once the trait portfolio caught up. The methodology produced a full pricing strategy: a five-step new-product pricing process anchored to a weighted incremental-benefits formula, a lifecycle-aware nine-position price/value matrix, and an organizational framework with a Pricing Advisory Group and explicit exception protocols separating planning, implementation, and adjustment.

Pricing strategy, methodology, and process redesign adopted; framework subsequently applied to new-product introductions and ongoing list-price setting across the portfolio.

A building materials supplier emerged from the financial crisis with margin compression across the customer book, inconsistent pricing across regions, and a sales force trained to win volume rather than to defend value. Demand had not recovered; price discipline had degraded; and several large accounts had been quietly migrated onto terms the business could not sustain.

The engagement produced a portfolio-wide reset: customer segmentation by economic value, identification of the value-based revenue layer that had been given away through under-pricing, and a bid framework with floor prices and discount authority calibrated to the strategic importance of each account. The work reframed the conversation from "what discount will close this deal" to "what is the lowest price at which we still want this customer."

Target Price / Sales 7%→12%; value-based revenue +35%; +25% improvement in global price alignment; total profit nearly doubled in a contracting market.

An Australian payments and transactional banking services provider serving a network of credit unions and mutual financial institutions prepared to introduce a mobile banking offering across its tiered customer base. The pricing question carried particular complexity because the company sat in two roles relative to its market — vendor to its member institutions for the new mobile services, and party to supplier-customer relationships with several financial institutions in the broader payments ecosystem who needed access to the company's payment infrastructure. Distinct pricing frameworks were required for two materially different buyer types.

For both, a bilateral value-based pricing methodology was applied. On the member-customer side, Economic Value Analysis quantified the mobile offering against principal alternatives — core banking system providers, in-house solutions, and independent mobile development shops — across functionality, interaction quality, business value, and total cost of ownership. The resulting Customer Value Ratio of approximately 1.10 against core banking established a defensible maximum price premium of roughly 16% in total cost of ownership terms.

In parallel, the value of each customer tier to the company was quantified — revenue potential, transaction volume, growth trajectory, willingness and ability to pay, marketing and operating cost efficiency — producing tier-specific premium adjustments calibrated to price sensitivity. A three-tier structure was developed with implementation fees and tiered annual license fees set to capture incremental value while reflecting the larger price sensitivity of smaller institutions. The same bilateral framework was applied separately to the access-seeker relationships, yielding a distinct price-differential calculation tied to the specific value the company and each access seeker provided each other.

Pricing methodology, three-tier structure, and working pricing tool adopted; bilateral framework subsequently applied across additional service offerings and to access-seeker relationships in the payments ecosystem.

An enterprise software company (subsequently acquired by a major industry consolidator) needed a pricing framework for a multi-module offering: a Strategy Management tool, a Compliance suite covering documentation and testing, and a Remediation module that represented the company's principal differentiator. Each module had a different competitive set, a different value proposition, and a different segment-specific economic logic.

A bilateral value-based pricing methodology was developed that calculated, for each module and segment, both a premium reflecting the value of the offering to the customer (importance × probability-of-impact × dollar-impact across operational, planning, and strategic value chains) and a discount reflecting the value of that customer to the seller (potential follow-on revenue, reference value, product feedback, cross-sell opportunity, channel cost). Six segments were defined along functionality and user-count dimensions, each with its own price line. The same apparatus is now in the Workbench.

Module-level pricing architecture adopted; methodology became the foundation for subsequent maintenance pricing and account-level negotiation.

The diagnostics division of a global pharmaceutical group brought a new DNA-based test platform to market during the AIDS epidemic, offering fast and accurate viral identification at a moment when speed and accuracy carried unusually high clinical and economic weight. As the sole provider of the underlying technology, the company faced a market-entry question without competitive price anchors: how to price a category-defining capability when there was no comparable offering to reference, and how to capture the differential value the platform created across very different clinical and institutional buyers.

Pricing was developed by calculating, for each of seven market segments, the specific incremental clinical and economic benefits the platform delivered to that segment — reflecting the relative importance of attributes that mattered differently to academic medical centers, public health agencies, reference laboratories, and other buyer types. In parallel, the value of each segment to the company was calculated — reference value, volume potential, learning curve effects, methodology extensibility — and used to adjust the segment-specific price points. The methodology was then operationalized through field-level pricing and negotiating tools, including price corridors that gave country and regional teams calibrated discretion within defensible bounds.

The platform methodology was subsequently extended as the underlying technology was applied to the identification of additional viruses, with the segment-specific pricing architecture and the field-level corridors carrying forward across the expansion.

Pricing architecture adopted across the launch and subsequently extended as the platform was applied to additional viral and clinical applications; methodology became foundational for the diagnostics division's pricing across the platform's product expansion.

A global pharmaceutical group prepared the launch of a new therapeutic across four Latin American markets, each with materially different reimbursement environments, payer dynamics, competitive sets, and regulatory pathways. Pricing decisions made at launch were known to be sticky — both within each country and across the regional reference network — so the launch sequence and the launch prices had to be set with explicit awareness of how each decision would propagate.

Country-specific pricing was developed using value-based positioning calibrated to local payer logic, with reference-pricing dynamics modeled across the four-country sequence. Launch order was treated as a decision variable rather than an operational detail. Comparable methodology has since been applied across European and fifteen-market international launches with similar reference-pricing structures.

Launch pricing strategy adopted across the four-country sequence; methodology subsequently applied to additional therapeutic launches in the same regional and reference-pricing structures.